U.S. panel sets deadline for Trump to decide participation in impeachment hearings
A U.S. congressional panel on Friday gave President Donald Trump one week to say whether his legal counsel intends to introduce evidence and call witnesses...
Deadline set for Trump to decide participation in impeachment hearings
A U.S. congressional panel gave President Donald Trump one week to say whether his legal counsel intends to introduce evidence and call witnesses in upcoming...
Exclusive: EU antitrust regulators say they are investigating Google’s data collection
EU antitrust regulators are investigating Google’s collection of data, the European Commission told Reuters on Saturday, suggesting the world’s most popular internet search engine remains...
Made of money? Russia artist and billionaire make $1 mln throne
Visitors of Moscow’s Art Residence have the opportunity to sit on wads of cash at a new art installation – a throne stuffed with a...
Made of money? Russia artist and billionaire make $1 mln throne
Visitors of Moscow’s Art Residence have the opportunity to sit on wads of cash at a new art installation – a throne stuffed with a...
China to use drug bulk-buy program to close price gap
China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said...
Search ends for survivors of Albanian quake as death toll reaches 51
Albania ended its search on Saturday for survivors of a powerful earthquake that killed 51 people, and buried more victims of the disaster including toddler...
Dining and Down Syndrome, a winning combination for Brussels restaurant
Brussels restaurant 65 Degres has become the city’s best-rated eatery, largely thanks to rave reviews of its staff, most of whom have Down Syndrome....
Dining and Down Syndrome, a winning combination for Brussels restaurant
Brussels restaurant 65 Degres has become the city’s best-rated eatery, largely thanks to rave reviews of its staff, most of whom have Down Syndrome....
Morphosys CFO says tafasitamab drug sales potential above $1 billion: magazine
German biotech company Morphosys’ tafasitamab, the group’s most advanced drug which is currently being tested, has sales potential of significantly more than $1 billion a...